Copy Number Signatures and Clinical Outcomes in Upper Tract Urothelial Carcinoma.

Bao Guan, Yuan Liang, Huan Lu, Zhengzheng Xu, Yue Shi, Juan Li, Wenwen Kong, Chuanyu Tian, Yezhen Tan, Yanqing Gong, Jin Liu, Dong Fang, Qi Shen, Shiming He, Muhammad Shakeel, Zhongyuan Zhang, Qun He, Xuesong Li, Weimin Ci, Liqun Zhou
Author Information
  1. Bao Guan: Department of Urology, Peking University First Hospital, Beijing, China.
  2. Yuan Liang: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  3. Huan Lu: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  4. Zhengzheng Xu: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  5. Yue Shi: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  6. Juan Li: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  7. Wenwen Kong: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  8. Chuanyu Tian: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  9. Yezhen Tan: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  10. Yanqing Gong: Department of Urology, Peking University First Hospital, Beijing, China.
  11. Jin Liu: Department of Urology, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
  12. Dong Fang: Department of Urology, Peking University First Hospital, Beijing, China.
  13. Qi Shen: Department of Urology, Peking University First Hospital, Beijing, China.
  14. Shiming He: Department of Urology, Peking University First Hospital, Beijing, China.
  15. Muhammad Shakeel: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  16. Zhongyuan Zhang: Department of Urology, Peking University First Hospital, Beijing, China.
  17. Qun He: Department of Urology, Peking University First Hospital, Beijing, China.
  18. Xuesong Li: Department of Urology, Peking University First Hospital, Beijing, China.
  19. Weimin Ci: Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  20. Liqun Zhou: Department of Urology, Peking University First Hospital, Beijing, China.

Abstract

Tumor staging of upper tract urothelial carcinomas (UTUCs) is relatively difficult to assert accurately before surgery. Here, we used copy number (CN) signatures as a tool to explore their clinical significance of molecular stratification in UTUC. CN signatures were extracted by non-negative matrix factorization from the whole-genome sequencing (WGS) data of 90 Chinese UTUC primary tumor samples. A validation UTUC cohort ( = 56) and a cohort from urinary cell-free DNA (cfDNA) of urothelial cancer patients ( = 94) and matched primary tumors were also examined. Survival analyses were measured using the Kaplan-Meier, and Cox regression was used for multivariate analysis. Here, we identified six CN signatures (Sig1-6). Patients with a high contribution of Sig6 (Sig6high) were associated with higher microsatellite instability level and papillary architecture and had a favorable outcome. Patients with a low weighted genome integrity index were associated with positive lymph node and showed the worst outcome. Sig6high was identified to be an independently prognostic factor. The predictive significance of CN signature was identified by a validation UTUC cohort. CN signatures retained great concordance between primary tumor and urinary cfDNA. In conclusion, our results reveal that CN signature assessment for risk stratification is feasible and provides a basis for clinical studies that evaluate therapeutic interventions and prognosis.

Keywords

References

  1. Gut. 2007 May;56(5):601-5 [PMID: 16973716]
  2. Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947 [PMID: 30371878]
  3. J Natl Cancer Inst. 2018 Mar 1;110(3): [PMID: 29584920]
  4. Urology. 2005 Jun;65(6):1233-7 [PMID: 15922421]
  5. Eur J Cancer. 1992;29A(1):69-75 [PMID: 1445749]
  6. Genome Res. 2014 Dec;24(12):2022-32 [PMID: 25236618]
  7. Sci Transl Med. 2013 Aug 7;5(197):197ra102 [PMID: 23926200]
  8. Ren Fail. 2016 Jun;38(5):663-70 [PMID: 26956094]
  9. Exp Mol Pathol. 2018 Jun;104(3):161-169 [PMID: 29608913]
  10. Sci Transl Med. 2013 Aug 7;5(197):197ra101 [PMID: 23926199]
  11. Nucleic Acids Res. 2018 Jan 4;46(D1):D14-D20 [PMID: 29036542]
  12. Mol Oncol. 2016 Mar;10(3):494-502 [PMID: 26778171]
  13. Environ Mol Mutagen. 2013 Jan;54(1):1-7 [PMID: 23238808]
  14. Nat Med. 2019 Oct;25(10):1526-1533 [PMID: 31570822]
  15. Clin Chem. 2020 Jan 1;66(1):188-198 [PMID: 31811000]
  16. Proc Natl Acad Sci U S A. 2012 May 22;109(21):8241-6 [PMID: 22493262]
  17. Urology. 2002 May;59(5):681-7 [PMID: 11992840]
  18. Nat Genet. 2018 Sep;50(9):1262-1270 [PMID: 30104763]
  19. Clin Cancer Res. 2009 Feb 15;15(4):1417-27 [PMID: 19193619]
  20. Genomics Proteomics Bioinformatics. 2017 Feb;15(1):14-18 [PMID: 28387199]
  21. Eur Urol. 2018 Jan;73(1):111-122 [PMID: 28867446]
  22. Nat Protoc. 2012 May 03;7(6):1024-41 [PMID: 22555242]
  23. Cancer Res. 2014 Sep 1;74(17):4853-4863 [PMID: 24970479]
  24. Nat Genet. 2013 Oct;45(10):1134-40 [PMID: 24071852]
  25. Nat Biotechnol. 2011 Jan;29(1):24-6 [PMID: 21221095]
  26. Theranostics. 2020 Mar 4;10(10):4323-4333 [PMID: 32292497]
  27. Genome Med. 2016 Nov 15;8(1):121 [PMID: 27846907]
  28. Elife. 2018 Sep 04;7: [PMID: 30178746]
  29. Nat Genet. 2011 Aug 07;43(9):875-8 [PMID: 21822268]
  30. Eur Urol. 2015 Nov;68(5):868-79 [PMID: 26188393]

Word Cloud

Created with Highcharts 10.0.0CNsignaturesUTUCurothelialprimarycohortidentifiedsignatureuppertractusedcopynumberclinicalsignificancestratificationwhole-genomesequencingtumorvalidation=urinarycell-freeDNAcfDNAPatientsSig6highassociatedoutcomeprognosisTumorstagingcarcinomasUTUCsrelativelydifficultassertaccuratelysurgerytoolexploremolecularextractednon-negativematrixfactorizationWGSdata90Chinesesamples56cancerpatients94matchedtumorsalsoexaminedSurvivalanalysesmeasuredusingKaplan-MeierCoxregressionmultivariateanalysissixSig1-6highcontributionSig6highermicrosatelliteinstabilitylevelpapillaryarchitecturefavorablelowweightedgenomeintegrityindexpositivelymphnodeshowedworstindependentlyprognosticfactorpredictiveretainedgreatconcordanceconclusionresultsrevealassessmentriskfeasibleprovidesbasisstudiesevaluatetherapeuticinterventionsCopyNumberSignaturesClinicalOutcomesUpperTractUrothelialCarcinomacarcinoma

Similar Articles

Cited By